Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Pilot Study of Sustained Release Bimatoprost Implant with SpyGlass Intraocular Lens: 3-Year Results.

Ophthalmology and therapy·2026
Same author

Histopathological Changes After Standard and Novel Endoscopic Cyclophotocoagulation versus Transscleral Cyclophotocoagulation in Human Cadaveric Eyes.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

A Systematic Review of the PAUL Glaucoma Implant.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

One year clinical outcomes with a novel canaloplasty device in mild to severe open angle glaucoma.

International journal of ophthalmology·2025
Same author

Acute Structural Effects of Novel Endoscopic Cyclophotocoagulation versus Standard Endoscopic and Transscleral Cyclophotocoagulation.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

ChatGPT Assisting Diagnosis of Neuro-Ophthalmology Diseases Based on Case Reports.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025

Related Experiment Video

Updated: Jul 16, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Developments in dosing aids and adherence devices for glaucoma therapy: current and future perspectives.

Malik Y Kahook1

  • 1Rocky Mountain Lions Eye Institute, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA. malik.kahook@gmail.com

Expert Review of Medical Devices
|March 16, 2007
PubMed
Summary

Glaucoma patients struggle with eye drop adherence due to various factors. This review examines current adherence aids and suggests future innovations for better glaucoma treatment compliance.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jul 16, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects
06:19

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Area of Science:

  • Ophthalmology
  • Medical Devices
  • Patient Adherence

Background:

  • Glaucoma is a primary cause of global blindness.
  • Topical eye drops are the standard treatment for chronic glaucoma.
  • Patient adherence to topical therapy is often poor due to forgetfulness, complex dosing, and physical challenges.

Purpose of the Study:

  • To review existing dosing and adherence aids for glaucoma patients.
  • To provide insights into potential improvements for future adherence technologies.

Main Methods:

  • Literature review of current glaucoma medication adherence aids.
  • Analysis of factors affecting patient compliance with topical treatments.
  • Discussion of emerging technologies and future device concepts.

Main Results:

  • Several dosing and adherence aids are currently available to assist glaucoma patients.
  • Existing aids aim to mitigate issues like forgetfulness and complex regimens.
  • Future devices hold promise for enhancing adherence through improved design and functionality.

Conclusions:

  • Adherence aids are crucial for effective glaucoma management.
  • Innovations in device technology are needed to overcome current limitations and improve patient outcomes in glaucoma care.